Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.

FDA Advisory Committee Feature image
AdComm endorsed Cyramza labeling expansion by slimmest of margins but overwhelmingly recommended against Tookad's approval.

A US Food and Drug Administration advisory committee on 26 February narrowly endorsed a labeling expansion for Eli Lilly & Co.’s Cyramza (ramucirumab) in lung cancer but overwhelmingly said Steba Biotech’s prostate cancer therapy Tookad (padeliporfin di-potassium powder) is not ready for approval.

By a one-vote margin, the Oncologic Drugs Advisory Committee endorsed the benefit/risk profile for ramucirumab, in combination with Genentech...

More from US FDA Performance Tracker

More from Regulatory Trackers